Faculty profile

Christine Desbiens

Back to faculty

Clinical Associate ProfessorCentre de recherche sur le cancerUniversité Laval

Christine Desbiens

Clinical Associate Professor

Centre de recherche sur le cancer

Université Laval

Quebec City, Quebec, Canada

Supervision signals

Clinical faculty often co-supervise; many graduate programs need a core faculty member as the main supervisor.
36 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

2,059

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their Université Laval profile.

Latest papers

Corrigendum to "First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?" [Cancer Treat. Rev. 135 (2025) 102909].
Cancer treatment reviews · 2026
Genetic counseling services for hereditary breast and ovarian cancer: patients' experience and satisfaction with different service models.
European journal of human genetics : EJHG · 2026
Development and Evaluation of a Web-Based App for Adverse Effect Management in Breast Cancer Patients Treated with Oral Targeted Therapy or Chemotherapy: Findings from a Pilot Study.
Current oncology (Toronto, Ont.) · 2026

All 78 publications

Latest funding

LAVIE: Living Labs for Oncology Supportive Care and Rehabilitation
CFI · 2025 · Co-investigator
$1,500,000

All 1 grants and awards

78 publications.

Corrigendum to "First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?" [Cancer Treat. Rev. 135 (2025) 102909].

Nguyen Van Long F, Poirier B, Desbiens C, Perron M, Paquet C, Ouellet C, Diorio C, Lemieux J, Nabi H

Cancer treatment reviews20261 citationsOpen Access

DOI: 10.1016/j.ctrv.2026.103088 PMID: 41605776

Genetic counseling services for hereditary breast and ovarian cancer: patients' experience and satisfaction with different service models.

Haroun O, Lapointe J, Guérard R, Bergeron AS, Raîche C, Chiquette J, Bouchard K, Pomey MP, Hébert J, Olivier Chevrier G, Lachapelle P, Omeranovic A, Côté M, Boily L, Brisson C, Gekas J, Cruz-Marino T, Touhami O, Blanchet Saint-Pierre A, Gagnon S, Boisvert K, Brousseau C, Castonguay L, Gosselin I, Renaud MC, Ruiz Mangas MG, Paquet-Beaupré A, Bélanger ME, Racine MM, Roy MC, Blanchette S, Faucher V, Leblanc J, Dubeau ME, Cavaillé M, Plante M, Desbiens C, Beaumont M, Simard J, Dorval M, Nabi H

European journal of human genetics : EJHG20261 citationsOpen Access

DOI: 10.1038/s41431-026-02031-y PMID: 41699267

Development and Evaluation of a Web-Based App for Adverse Effect Management in Breast Cancer Patients Treated with Oral Targeted Therapy or Chemotherapy: Findings from a Pilot Study.

Lemieux J, Côté I, Lemay M, Lauzier S, Després P, Desbiens C, Doyle C, Poirier B, Baghdadli A, Di Schiavi Trotta L, Nabi H

Current oncology (Toronto, Ont.)2026Open Access

DOI: 10.3390/curroncol33050272 PMID: 42187589

A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).

Stephen Chia, Andrew David Redfern, Jean-Pierre M. Ayoub, Haji Ibraheem Chalchal, Daniel Rayson, Moira Katherine Rushton, Christine Desbiens, Dhanusha Sabanathan, Jacques Raphael, Angela Chan, Jessica Singh, Christine E. Simmons, Nicholas Zdenkowski, Sheridan Marie Wilson, Danielle Lee Rodin, David W. Cescon, Frauke Schimmöller, Lisa Gallinaro, Bingshu E. Chen, Wendy R. Parulekar

Journal of Clinical Oncology202518 citationsOpen Access

DOI: 10.1200/jco.2025.43.17_suppl.lba1005

First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?

Nguyen Van Long F, Poirier B, Desbiens C, Perron M, Paquet C, Ouellet C, Diorio C, Lemieux J, Nabi H

Cancer treatment reviews20253 citationsOpen Access

DOI: 10.1016/j.ctrv.2025.102909 PMID: 40054315

Comparative effectiveness of opioid versus opioid-free analgesia after outpatient breast surgery: PAIN-Alt trial protocol.

Fiore JF, Shirzadi S, Roversi K, Prakash I, Wong S, Meterissian S, Meguerditchian AN, Desbiens C, Rivard J, Delisle M, Findlay-Shirras L, Abou Khalil J, Maciver A, Quan ML, Verreault K, Johnston S, Feldman L, McDonald EG, Postoperative Analgesia Intervention with Non-opioid Alternatives (PAIN-Alt) Collaboration

BMJ open20252 citationsOpen Access

DOI: 10.1136/bmjopen-2025-107258 PMID: 41193191

Supplementary File 1 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer

Anil Abraham Joy, Nicholas Cheng, Karen A. Gelmon, Mihaela Mates, Christine Desbiens, Mark J. Clemons, Sara Taylor, Julie Lemieux, Angela DeLuca, Louis Gasparini, Ilinca M. Lungu, David M. Soave, Alexander Fortuna, Trevor J. Pugh, Shuo Shuo Liu, John M.S. Bartlett, Philip Awadalla, Melanie Spears, Bingshu E. Chen, Jane Bayani, Wendy R. Parulekar

2025Open Access

DOI: 10.1158/2767-9764.30609195

Supplementary Figure S1 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer

2025Open Access

DOI: 10.1158/2767-9764.30609222

Supplementary Figure S3 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer

2025Open Access

DOI: 10.1158/2767-9764.30609216

Table 1 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer

2025Open Access

DOI: 10.1158/2767-9764.30609183

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Christine Desbiens

Research

Latest papers

Latest funding

Corrigendum to "First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?" [Cancer Treat. Rev. 135 (2025) 102909].

Genetic counseling services for hereditary breast and ovarian cancer: patients' experience and satisfaction with different service models.

Development and Evaluation of a Web-Based App for Adverse Effect Management in Breast Cancer Patients Treated with Oral Targeted Therapy or Chemotherapy: Findings from a Pilot Study.

First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?

Comparative effectiveness of opioid versus opioid-free analgesia after outpatient breast surgery: PAIN-Alt trial protocol.

Supplementary File 1 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer

Supplementary Figure S1 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer

Supplementary Figure S3 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer

Table 1 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer

LAVIE: Living Labs for Oncology Supportive Care and Rehabilitation

Frequent collaborators

Anil Joy

Wendy Parulekar

Bingshu Chen

David Soave

Melanie Spears

Mark Clemons

Philip Awadalla

Trevor Pugh

Caroline Diorio

Hermann Nabi

Michel Dorval

Catalin Mihalcioiu

Marie-Pascale Pomey

Gunita Mitera

Sophie Lauzier

Mark Basik

David Cescon

Gerald Batist

Steven Latosinsky

Jacques Simard